Page last updated: 2024-08-05 15:49:39

SMO receptor antagonist

An antagonist that interferes with the action of smoothened (SMO) receptor.

ChEBI ID: 66908

Members (3)

MemberDefinitionClass
gdc 0449A benzamide obtained by formal condensation between the carboxy group of 2-chloro-4-(methylsulfonyl)benzoic acid and the anilino group of 4-chloro-3-(pyridin-2-yl)aniline. Used for the treatment metastatic basal cell carcinoma.vismodegib
glasdegibA member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signalling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy.glasdegib
lde225A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.sonidegib

Research

Studies (794)

TimeframeStudies, Drugs with This Role(%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (1.51)29.6817
2010's548 (69.02)24.3611
2020's234 (29.47)2.80

Study Types

Publication TypeStudies, Drugs with this Role (%)All Drugs (%)
Trials113 (12.65%)5.53%
Reviews168 (18.81%)6.00%
Case Studies133 (14.89%)4.05%
Observational6 (0.67%)0.25%
Other473 (52.97%)84.16%

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)Drugs
EWS/FLI fusion proteinHomo sapiens (human)Potency9.347647
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.810711

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)Drugs
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC501.400011
Cytochrome P450 1A2Homo sapiens (human)IC5025.000022
Cytochrome P450 2C19Homo sapiens (human)IC5025.000022
Cytochrome P450 2C8Homo sapiens (human)IC5030.000011
Cytochrome P450 2C9 Homo sapiens (human)IC5025.000022
Cytochrome P450 2D6Homo sapiens (human)IC5025.000022
Cytochrome P450 3A4Homo sapiens (human)IC5025.000022
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC5033.000011
Smoothened homologHomo sapiens (human)IC500.022288
Smoothened homologMus musculus (house mouse)IC500.062789
Smoothened homologHomo sapiens (human)Ki0.011523
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC500.020011
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC500.020011
Sonic hedgehog proteinHomo sapiens (human)IC500.882522
Sonic hedgehog proteinMus musculus (house mouse)IC500.007234

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)Drugs
AlbuminHomo sapiens (human)Kd65.375044
AlbuminRattus norvegicus (Norway rat)Kd105.600033
Smoothened homologHomo sapiens (human)EC500.002522
Smoothened homologMus musculus (house mouse)EC500.003422
Smoothened homologHomo sapiens (human)Kd0.097511

Other Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)Drugs
Cytochrome P450 2C9 Homo sapiens (human)INH20.000011
Cytochrome P450 3A4Homo sapiens (human)INH20.000011
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)INH20.000011
Sonic hedgehog proteinHomo sapiens (human)INH0.002811